Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy
Shots:
- The approval is based on P-II/III ALD-102 study evaluating Skysona in patients with an ABCD1 gene mutation aged <18 yrs. with CALD without matched sibling donors. The P-III ALD-104 study is ongoing
- Results: 90% of patients met the MFD-free survival 1EPs @24mos.- 26 out of 28 patients maintained an NFS ≤1 @24mos. All patients who completed ALD-102 enrolled for long-term follow-up in the LTF-304 study- in which therapy maintained MFD-free status through the last follow-up with mDoR of 3.2yrs. and 14 patients reached at least their year 5 follow-up visit
- Skysona is the 1st one-time gene therapy approved in the EU for CALD & MAA is currently under MHRA’s review in Great Britain
| Ref: Bluebird Bio | Image: SCRIP Intelligence
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com